These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25248409)

  • 1. Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.
    Filipović A; Lombardo Y; Faronato M; Abrahams J; Aboagye E; Nguyen QD; d'Aqua BB; Ridley A; Green A; Rahka E; Ellis I; Recchi C; Przulj N; Sarajlić A; Alattia JR; Fraering P; Deonarain M; Coombes RC
    Breast Cancer Res Treat; 2014 Nov; 148(2):455-62. PubMed ID: 25248409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
    Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
    J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological and clinical implications of nicastrin expression in invasive breast cancer.
    Filipović A; Gronau JH; Green AR; Wang J; Vallath S; Shao D; Rasul S; Ellis IO; Yagüe E; Sturge J; Coombes RC
    Breast Cancer Res Treat; 2011 Jan; 125(1):43-53. PubMed ID: 20224929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo.
    Lombardo Y; Filipović A; Molyneux G; Periyasamy M; Giamas G; Hu Y; Trivedi PS; Wang J; Yagüe E; Michel L; Coombes RC
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16558-63. PubMed ID: 23012411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicastrin mutations in familial acne inversa impact keratinocyte proliferation and differentiation through the Notch and phosphoinositide 3-kinase/AKT signalling pathways.
    Xiao X; He Y; Li C; Zhang X; Xu H; Wang B
    Br J Dermatol; 2016 Mar; 174(3):522-32. PubMed ID: 26473517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
    Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
    Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
    Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
    EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.
    Fu M; Maresh EL; Helguera GF; Kiyohara M; Qin Y; Ashki N; Daniels-Wells TR; Aziz N; Gordon LK; Braun J; Elshimali Y; Soslow RA; Penichet ML; Goodglick L; Wadehra M
    Mol Cancer Ther; 2014 Apr; 13(4):902-15. PubMed ID: 24448822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.
    Hsu EC; Kulp SK; Huang HL; Tu HJ; Salunke SB; Sullivan NJ; Sun D; Wicha MS; Shapiro CL; Chen CS
    Neoplasia; 2015 Jun; 17(6):497-508. PubMed ID: 26152358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin.
    Hayashi I; Takatori S; Urano Y; Miyake Y; Takagi J; Sakata-Yanagimoto M; Iwanari H; Osawa S; Morohashi Y; Li T; Wong PC; Chiba S; Kodama T; Hamakubo T; Tomita T; Iwatsubo T
    Oncogene; 2012 Feb; 31(6):787-798. PubMed ID: 21725355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
    Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK
    Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional inactivation of nicastrin restricts amyloid deposition in an Alzheimer's disease mouse model.
    Sesele K; Thanopoulou K; Paouri E; Tsefou E; Klinakis A; Georgopoulos S
    Aging Cell; 2013 Dec; 12(6):1032-40. PubMed ID: 23826707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
    Lee HW; Kim SJ; Choi IJ; Song J; Chun KH
    Clin Exp Metastasis; 2015 Aug; 32(6):593-603. PubMed ID: 26134677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.